Myriad Pharmaceuticals Q2 2009 Net Loss Narrows Down
The company has incurred an operating loss of $15.1m for the three months ended December 31, 2009 as compared to $17.1m for the same period in 2008. The
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).
The growth is primarily driven by exploration of factors influencing cellular malfunction and disease development. Additionally, innovations in epigenetic studies such as biomarker discovery and scientifically useful biomarker